: iStockAnalyst.com Symbols Feed

BioMedReports FDA Calendar: 19 Hot Summer Trades

Wed, 17 Jun 2009 12:13:04 GMT

Below is a sample of entries from the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The companies outlined below have expected FDA new drug product decisions or clinical trial results expected over the next three months of summer. The list also includes some Extreme Trades of companies with market caps below $250 million that have pending clinical trial results or FDA decisions that could have a major stock price impact. Rigel Pharma (NASDAQ:RIGL): On 5/5/09, (...)[More...]

Rigel And Seattle Genetics -The Delicate Art Of Expectation Management

Tue, 10 Feb 2009 04:10:00 GMT

In the previous article, I discussed the pharmaceutical industry’s race after approved drugs and late stage agents with proof of concept in humans. I mentioned Rigel’s (RIGL) lead drug, R788, as a likely target for collaboration due to its impressive activity, the huge addressable market and the fact it is an oral drug. For the past year,[More...]

Biotech Portfolio Updates - Rigel Is Still On Track, Pfizer May Have Found Its Next Blockbuster

Fri, 09 Jan 2009 14:06:00 GMT

In the pharmaceutical industry, 2008 will probably be marked by the big pharmas’ insatiable appetite for new drugs. Threatened by fierce generic competition, the pharmaceutical giants were not only eager to pay generous acquisition premiums for marketed[More...]

Immunogen and Exelixis Defy the Myth of Recession

Sun, 21 Dec 2008 01:09:00 GMT

[More...]

Rigel Pharmaceuticals– Crisis Or Opportunity?

Mon, 10 Nov 2008 13:52:00 GMT

The past two weeks were anything but easy for Rigel’s (RIGL) shareholders, who saw their shares crash more than 50%. Rigel started 2008 on the right foot after a 200% jump in a single day last December, following impressive data for the company’s flagship[More...]

When There Is Blood In The Streets - Buy Biotech

Fri, 10 Oct 2008 23:32:00 GMT

History has shown again and again that times like these represent a huge long term buying opportunity. This may be particularly true for the biotech segment that, despite weathering the storm better than other segments, has had its share of price declines. During the past several weeks, great biotech stocks, from small early stage companies to fully commercialized companies have been thrown out of portfolios like bad auction rate securities, but the truth is that the value proposition of most of these biotechs did not change at all, and is not likely to change as a result of market conditions. This is why current prices create the best opportunity to get into the[More...]

Periodicals Wrap-Up for Tuesday, August 19

Tue, 19 Aug 2008 14:19:00 GMT

Posted By Optiondragon for myhappytrading, a website made by traders for traders.[More...]

Periodicals Wrap-Up for Tuesday, May 27th

Tue, 27 May 2008 14:02:41 GMT

Submitted By optiondragon[More...]

Airline volume takes off after Lufthansa buys stake in JetBlue

Fri, 14 Dec 2007 15:51:54 GMT

Today’s tickers: JBLU, NWA, BBH, BIIB, RIGL, C, LEH, WM, COST, VIX JBLU – Consolidation-mongerers finally got their fix today on news that Europe’s second-biggest airline, Lufthansa, bought a 19% minority stake in discount carrier JetBlue. Trading was halted on JetBlue shares earlier in the day, but stocks quickly advanced 14% on the report, closing at $7.15 this afternoon. Options in the airline traded at more than 9 times the average volume, and we observed plenty...[More...]

Stagflation

Fri, 14 Dec 2007 14:18:58 GMT

Good morning. Much like yesterday, we're set for a weak open following the higher than expected CPI. Consumer prices rose +0.8% in November the fastest pace for more than two years. To make matters worse, we have a report from ComScore that hints toward a disappointing online retail sales, Greenspan issuing a warning...[More...]

Rigel Pharmaceuticals Prices Public Offer at $7.25

Fri, 18 Sep 2009 13:47:00 GMT

Rigel Pharmaceuticals, a US-based drug development company, has priced an underwritten public offering of 13 million of its common stock at $7.25 per share.
All of the shares are being offered by Rigel.
The underwriters have an option to purchase up to an additional 1.95 million shares to cover over-allotments, if any.

[More...]

Rigel Reports $33.4 Million Q4 Loss

Tue, 24 Feb 2009 12:13:59 GMT

San Francisco-based pharmaceutical company Rigel Pharmaceuticals has reported a net loss of $33.4 million, or $0.91 per share, for the fourth quarter of 2008, compared to a net loss of $19 million, or $0.61 per share, for the same period of 2007. Weighted average shares outstanding for the fourth quarters of 2008 and 2007 were 36.6 million and 31.1 million, respectively.[More...]

Rigel Announces Second Quarter 2009 Financial Results

Tue, 04 Aug 2009 11:46:00 GMT

SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2009.
"With the results from our Phase 2b clinical trials for R788 now in hand, our focus is to secure a collaboration partner for R788," said James M. Gower, chairman and chief executive officer of Rigel.
There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials, potential problems that may arise in the clinical testing and approval process, Rigel's expected dependence upon reaching an agreement with a collaboration partner for R788 and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-Q for the three months ended March 31, 2009.

[More...]

The Rosen Law Firm, P.A. Encourages Rigel Pharmaceuticals, Inc. Shareholders to Evaluate Their Legal Rights

Fri, 31 Jul 2009 15:19:00 GMT

The Rosen Law Firm, P.A. is investigating the conduct of Rigel Pharmaceuticals, Inc. and its board of directors as a result of allegations made in a recently filed proposed class action lawsuit pending in the United States District Court for the Northern District of California.[More...]

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

Thu, 23 Jul 2009 21:56:00 GMT

Rigel Pharmaceuticals, Inc. today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis patients who had failed to respond to at least one biologic treatment, the group treated with R788 did not report significantly higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group at three months, and therefore, the trial failed to meet its efficacy endpoints. The objective components * of these ACR scores did show a statistically significant difference; however, the subjective reported response rate components did not as compared to placebo. Although the ACR scores for the R788 group were within the expected range in this patient population, the reported placebo response rates were considerably higher than seen in any other previous study of RA biologic failure patients and rose unaccountably between week 6 and month 3 . TASKi3 was the first clinical trial evaluating R788 in which anatomical changes in the patients' wrist and hands were evaluated using Magnetic Resonance Imaging and scored using the RAMRIS system. Those results showed improvements in the treated group versus the placebo group in the Synovitis and Osteitis scores, while the Erosion scores, known to be the slowest to change, showed no significant effect at three months. The most frequent adverse events were as expected from the earlier TASKi trials and appear to be manageable.Rigel will host a conference call today at 7PM EDT/ 4PM PDT to discuss these results . 'Our objective with R788 in RA is to position the product after methotrexate and before biological therapies are used. We have shown excellent results in that patient population in our earlier TASKi1 and TASKi2 studies, and we believe that patient population represents the large market opportunity for this product,' said James M. Gower, chairman and chief executive officer of Rigel. 'In this TASKi3 patient population, biologic failures, we have seen divergent results as sometimes happens in studies with subjective components. However, we are pleased to see excellent results in the objective measures and in the Synovitis and Osteitis MRI scores,' he added. *blood measurements of C-Reactive Protein and Erythrocyte Sedimentation Rate Efficacy Results[More...]

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis

Thu, 23 Jul 2009 15:57:00 GMT

Rigel Pharmaceuticals, Inc. today announced that the Company plans to host a conference call on Thursday, July 23, 2009 at 7:00 pm EDT . Members of Rigel's senior management team and the principal investigator of the trial will discuss results of the Company's Phase 2b TASKi3 clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters. Conference Call and Webcast InformationTo access the live call, please dial 866-700-6293 or 1-617-213-8835 10 minutes prior to the start time and use the passcode 13318888. A replay of the call will be available at approximately 10:00 pm EDT/7:00 pm PDT on July 23, 2009 until July 30, 2009. To access the replay, please dial 888-286-8010 or 1-617-801-6888 and use the passcode 14211103. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.About Rigel Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.[More...]

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

Thu, 09 Jul 2009 00:55:00 GMT

Rigel Pharmaceuticals, Inc. today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT . Members of Rigel's senior management team and the principal investigator of the trial will discuss results of the Company's Phase 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters.[More...]

Rigel to Present at Jefferies Healthcare Conference

Wed, 10 Jun 2009 11:26:00 GMT

Rigel Pharmaceuticals, Inc. today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 3rd Annual Healthcare Conference in New York City on Thursday, June 18th at 3:15 p.m. EDT.[More...]

Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers

Mon, 01 Jun 2009 11:26:00 GMT

Rigel Pharmaceuticals, Inc. today announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute , part of the U.S. National Institutes of Health. This open-label, single arm clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.[More...]

Rigel to Present at JMP Securities Research Conference

Wed, 13 May 2009 11:26:00 GMT

Rigel Pharmaceuticals, Inc. today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 8th Annual JMP Securities Research Conference in San Francisco on Wednesday, May 20th at 2:00 p.m. PT.[More...]

Rigel Announces First Quarter 2009 Financial Results

Tue, 05 May 2009 11:49:00 GMT

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2009.
In the first quarter of 2009, Rigel recorded a federal refundable tax benefit of approximately $66,000, which was calculated in accordance with The American Recovery and Reinvestment Act of 2009.
"We expect to deliver top-line results in July 2009 from both our TASKi2 and TASKi3 clinical trials," said James M. Gower, chairman and chief executive officer of Rigel.

[More...]

Rigel to Present at Citi's Biotech Day

Fri, 27 Mar 2009 11:25:00 GMT

Rigel Pharmaceuticals, Inc. today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at Citi's 4th Annual Biotech Day in New York City on Wednesday, April 1st at 10:40 a.m. EDT.[More...]